**AI生物科技新星CellVoyant完成760万英镑种子轮融资**
英国布里斯托大学孕育的AI生物科技初创公司CellVoyant近日宣布，已成功获得760万英镑的种子轮融资，这标志着其在利用人工智能推动干细胞疗法开发的道路上迈出了坚实的一步。本轮融资由知名投资机构Octopus Ventures领投，同时获得了Horizons Ventures、Air Street Capital以及Verve Ventures的积极参与。
CellVoyant专注于利用先进的人工智能成像技术，为干细胞疗法的制造商提供高效解决方案，以加速新疗法的研发和生产。这一创新技术有望打破传统方法的限制，提高治疗效率，降低生产成本，为全球医疗健康领域带来革命性的变化。
此次资金注入将为CellVoyant提供必要的资源，加速其技术的研发和市场推广，同时可能吸引更多合作伙伴，共同探索在生物科技领域的更多可能性。随着全球对精准医疗和个性化治疗需求的增长，CellVoyant的发展前景显得尤为广阔。
CellVoyant的首席执行官表示：“我们非常荣幸能得到这些知名投资机构的支持，他们的信任不仅验证了我们的技术潜力，也为CellVoyant的未来发展注入了强大动力。我们将继续致力于利用人工智能推动干细胞疗法的进步，为患者带来更有效的治疗选择。”
此次融资事件在生物科技界引起了广泛关注，预示着AI技术在医疗领域的应用将进一步深化，同时也体现了投资者对CellVoyant创新能力和市场前景的高度认可。
英语如下：
**AI Biotech Startup CellVoyant Raises £7.6 Million Seed Funding, Pioneering Stem Cell Therapy Revolution**
Keywords: AI biotechnology, CellVoyant, seed funding
**AI biotech newcomer CellVoyant secures £7.6 million seed investment**
CellVoyant, an AI biotech startup hatched from the University of Bristol, has announced that it has successfully closed a £7.6 million seed funding round, marking a significant stride in its mission to harness artificial intelligence for stem cell therapy development. The round was led by prominent investor Octopus Ventures, with strong participation from Horizons Ventures, Air Street Capital, and Verve Ventures.
Specializing in advanced AI imaging technology, CellVoyant focuses on providing efficient solutions for stem cell therapy manufacturers, accelerating the development and production of new therapies. This innovative technology aims to overcome limitations of traditional methods, enhancing treatment efficiency and reducing production costs, thereby bringing about a revolutionary change in the global healthcare landscape.
The fresh funding will equip CellVoyant with the resources to hasten technology development and market expansion, potentially attracting more partners to explore further possibilities in the biotech sector. With the growing global demand for precision medicine and personalized treatments, CellVoyant’s prospects appear particularly promising.
The CEO of CellVoyant commented, “We are immensely proud to have the backing of these renowned investors. Their trust not only validates our technological potential but also injects a significant boost into CellVoyant’s future growth. We remain committed to advancing stem cell therapy through AI, offering patients more effective treatment options.”
This funding round has garnered substantial attention in the biotech industry, signaling a deeper integration of AI technology in healthcare and reflecting investors’ high confidence in CellVoyant’s innovation and market potential.
【来源】https://sifted.eu/articles/ai-biotech-cellvoyant-raise
Views: 1